Gilead Sciences

• 10-QQ2 FY2026Impairment / charge

  Filed Aug 6

  Acquisition charges and the EVOKE-03 failure overwhelmed growth in Biktarvy and Descovy, driving a GAAP loss.

  • Revenue$7.8BYoY +10.2%
  • Net income−$10.5Bvs $2.0B year ago

• 8-KEarningsGuidance loweredImpairment / charge

  Filed Aug 4

  Acquired IPR&D charges, led by Arcellx, drove a GAAP loss despite HIV, Trodelvy and Livdelzi sales growth.

Coverage: 10-K, 10-Q and 8-K filings filed since Jul 1, 2026.

Request longer coverage

Company data: Wikidata Q663596